JP2014518860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014518860A5 JP2014518860A5 JP2014509759A JP2014509759A JP2014518860A5 JP 2014518860 A5 JP2014518860 A5 JP 2014518860A5 JP 2014509759 A JP2014509759 A JP 2014509759A JP 2014509759 A JP2014509759 A JP 2014509759A JP 2014518860 A5 JP2014518860 A5 JP 2014518860A5
- Authority
- JP
- Japan
- Prior art keywords
- patients
- lixisenatide
- cases
- group
- injection group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 229960001093 lixisenatide Drugs 0.000 description 4
- 108010004367 lixisenatide Proteins 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11166052 | 2011-05-13 | ||
| EP11166052.8 | 2011-05-13 | ||
| PCT/EP2012/058779 WO2012156312A1 (en) | 2011-05-13 | 2012-05-11 | Pharmaceutical combination for use in the treatment of diabetes type 2 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014518860A JP2014518860A (ja) | 2014-08-07 |
| JP2014518860A5 true JP2014518860A5 (OSRAM) | 2015-06-18 |
| JP6005140B2 JP6005140B2 (ja) | 2016-10-12 |
Family
ID=46052773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509759A Expired - Fee Related JP6005140B2 (ja) | 2011-05-13 | 2012-05-11 | ２型糖尿病患者の治療において使用するための組合せ医薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130040878A1 (OSRAM) |
| EP (1) | EP2709652A1 (OSRAM) |
| JP (1) | JP6005140B2 (OSRAM) |
| KR (1) | KR20140041553A (OSRAM) |
| CN (2) | CN103648519A (OSRAM) |
| AR (1) | AR086356A1 (OSRAM) |
| AU (1) | AU2012257780B2 (OSRAM) |
| BR (1) | BR112013029256A8 (OSRAM) |
| CA (1) | CA2835336A1 (OSRAM) |
| MX (1) | MX356728B (OSRAM) |
| RU (2) | RU2017129878A (OSRAM) |
| WO (1) | WO2012156312A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| CA2780460C (en) | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| KR102165434B1 (ko) * | 2013-01-17 | 2020-10-14 | 브이티브이 테라퓨틱스 엘엘씨 | 2형 당뇨병 및 다른 장애의 치료를 위한 glp1r 작용제 및 메트포민의 조합 및 이것들의 사용법 |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| CN115461344B (zh) | 2020-04-01 | 2024-01-12 | 杭州中美华东制药有限公司 | 一种glp-1受体激动剂的晶型a及其制备方法 |
| WO2021196951A1 (zh) | 2020-04-01 | 2021-10-07 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| JP5980466B2 (ja) * | 2009-11-13 | 2016-08-31 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | インスリングラルギン及びメトホルミンへの付加療法を含む２型糖尿病の治療方法 |
| PL2324853T3 (pl) * | 2009-11-13 | 2016-01-29 | Sanofi Aventis Deutschland | Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2 |
| US20110118178A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) * | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
-
2012
- 2012-05-10 US US13/468,422 patent/US20130040878A1/en not_active Abandoned
- 2012-05-11 AR ARP120101668A patent/AR086356A1/es unknown
- 2012-05-11 KR KR1020137033311A patent/KR20140041553A/ko not_active Ceased
- 2012-05-11 EP EP12720196.0A patent/EP2709652A1/en not_active Withdrawn
- 2012-05-11 MX MX2013013198A patent/MX356728B/es active IP Right Grant
- 2012-05-11 WO PCT/EP2012/058779 patent/WO2012156312A1/en not_active Ceased
- 2012-05-11 RU RU2017129878A patent/RU2017129878A/ru not_active Application Discontinuation
- 2012-05-11 BR BR112013029256A patent/BR112013029256A8/pt not_active Application Discontinuation
- 2012-05-11 CA CA2835336A patent/CA2835336A1/en not_active Abandoned
- 2012-05-11 CN CN201280034724.7A patent/CN103648519A/zh active Pending
- 2012-05-11 CN CN201810748089.8A patent/CN109045283A/zh active Pending
- 2012-05-11 RU RU2013155480/15A patent/RU2013155480A/ru unknown
- 2012-05-11 JP JP2014509759A patent/JP6005140B2/ja not_active Expired - Fee Related
- 2012-05-11 AU AU2012257780A patent/AU2012257780B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014518860A5 (OSRAM) | ||
| JP2012529488A5 (OSRAM) | ||
| MX336657B (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
| JP2012255026A5 (OSRAM) | ||
| FI3628319T3 (fi) | Hepaattisen enkefalopatian hoito rifaksimiinilla | |
| JP2014533680A5 (OSRAM) | ||
| JP2012529485A5 (ja) | 赤血球凝固の予防及び治療のための組成物並びに方法 | |
| JP2012517449A5 (OSRAM) | ||
| WO2009104932A3 (ko) | 복합제제 | |
| NZ702801A (en) | Treatment of sanfilippo syndrome type b | |
| JP2014528901A5 (OSRAM) | ||
| HRP20171570T1 (hr) | Tapentadol za sprječavanje i liječenje depresije i tjeskobe | |
| JP2013541583A5 (OSRAM) | ||
| JP2013166781A5 (OSRAM) | ||
| NZ608266A (en) | Administration of lorcaserin to individuals with renal impairment | |
| JP2009541409A5 (OSRAM) | ||
| IL254641B2 (en) | Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption | |
| JP2012500261A5 (OSRAM) | ||
| RU2015143475A (ru) | Продукт и способ лечения диареи | |
| WO2010098627A2 (ko) | 약제학적 제제 | |
| EA201100916A1 (ru) | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| JP2015518002A5 (OSRAM) | ||
| Yang et al. | Beriberi disease: is it still present in the United States? | |
| JP2008189679A5 (OSRAM) |